See more : National Fertilizers Limited (NFL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Apyx Medical Corporation (APYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apyx Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Being Holdings Co., Ltd. (9145.T) Income Statement Analysis – Financial Results
- Terranet AB (TERRNT-B.ST) Income Statement Analysis – Financial Results
- Beijing Zhong Ke San Huan High-Tech Co., Ltd. (000970.SZ) Income Statement Analysis – Financial Results
- Wireless Xcessories Group, Inc. (WIRX) Income Statement Analysis – Financial Results
- Weimob Inc. (2013.HK) Income Statement Analysis – Financial Results
Apyx Medical Corporation (APYX)
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.35M | 44.51M | 48.52M | 27.71M | 28.15M | 16.69M | 38.88M | 36.63M | 29.52M | 27.68M | 23.66M | 27.67M | 25.41M | 24.23M | 26.95M | 28.10M | 28.78M | 26.68M | 20.21M | 20.50M | 16.55M | 12.45M | 11.48M | 9.94M | 9.60M | 8.44M | 7.37M | 7.49M | 5.52M |
| Cost of Revenue | 18.59M | 15.38M | 14.92M | 10.21M | 9.03M | 5.89M | 19.12M | 18.71M | 16.96M | 18.69M | 14.46M | 16.34M | 14.68M | 14.24M | 15.10M | 16.25M | 17.46M | 16.08M | 12.65M | 12.51M | 9.43M | 7.19M | 5.72M | 4.60M | 4.59M | 5.27M | 4.14M | 4.13M | 3.22M |
| Gross Profit | 33.76M | 29.13M | 33.60M | 17.50M | 19.13M | 10.79M | 19.76M | 17.92M | 12.56M | 8.99M | 9.20M | 11.33M | 10.73M | 9.99M | 11.85M | 11.85M | 11.32M | 10.60M | 7.56M | 7.98M | 7.12M | 5.26M | 5.76M | 5.34M | 5.01M | 3.17M | 3.23M | 3.35M | 2.31M |
| Gross Profit Ratio | 64.49% | 65.45% | 69.26% | 63.17% | 67.94% | 64.68% | 50.82% | 48.91% | 42.54% | 32.48% | 38.88% | 40.96% | 42.23% | 41.22% | 43.98% | 42.17% | 39.32% | 39.74% | 37.41% | 38.94% | 43.00% | 42.23% | 50.15% | 53.74% | 52.19% | 37.53% | 43.85% | 44.77% | 41.76% |
| Research & Development | 4.84M | 4.54M | 4.32M | 3.92M | 3.81M | 2.47M | 2.46M | 2.62M | 2.16M | 1.42M | 1.26M | 1.33M | 1.20M | 1.85M | 2.08M | 2.06M | 1.64M | 1.19M | 985.81K | 907.39K | 717.35K | 693.71K | 463.13K | 513.02K | 379.83K | 183.17K | 96.74K | 105.70K | 121.90K |
| General & Administrative | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.30M | 1.30M | 800.00K | 1.50M | 800.00K | 11.37M | 8.57M | 8.42M | 6.69M | 4.89M | 4.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 8.50M | 7.57M | 6.79M | 6.01M | 5.76M | 5.60M | 4.91M | 4.71M | 3.90M | 6.46M | 1.75M | 0.00 | 1.34M | 1.18M |
| Other Expenses | 0.00 | 509.00K | -373.00K | 479.00K | -382.00K | -203.00K | -11.37M | -8.57M | -8.42M | -6.69M | -4.89M | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.19K | 39.29K | 81.91K | 124.45K | 0.00 | 396.81K | 321.17K | 2.15M | 2.80M | 1.43M | 1.22M |
| Operating Expenses | 51.02M | 52.69M | 48.05M | 37.59M | 40.04M | 23.65M | 23.50M | 21.71M | 19.54M | 14.84M | 11.22M | 10.29M | 11.50M | 11.45M | 11.14M | 10.56M | 9.21M | 7.98M | 7.16M | 6.70M | 6.40M | 5.73M | 5.18M | 4.81M | 7.16M | 4.09M | 2.89M | 2.87M | 2.53M |
| Cost & Expenses | 69.61M | 68.07M | 62.97M | 47.79M | 49.07M | 29.55M | 42.62M | 40.42M | 36.51M | 33.53M | 25.69M | 26.63M | 26.18M | 25.70M | 26.24M | 26.81M | 26.67M | 24.05M | 19.81M | 19.22M | 15.84M | 12.92M | 10.90M | 9.41M | 11.75M | 9.36M | 7.03M | 7.01M | 5.74M |
| Interest Income | 921.00K | 157.00K | 11.00K | 241.00K | 1.39M | 616.00K | 0.00 | 0.00 | 1.00K | 0.00 | 7.00K | 0.00 | 12.00K | 0.00 | 24.36K | 48.76K | 142.72K | 103.09K | 46.96K | 3.26K | 2.98K | 5.21K | 10.11K | 28.75K | 0.00 | 4.16K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.48M | 15.00K | 10.00K | 46.00K | 8.00K | 104.00K | 136.00K | 158.00K | 158.00K | 151.00K | 237.00K | 232.00K | 249.00K | 223.00K | 76.37K | 58.46K | 2.47K | 16.16K | 22.70K | 15.09K | 34.06K | 48.45K | 70.69K | 66.80K | 0.00 | 103.84K | 0.00 | 75.80K | 68.70K |
| Depreciation & Amortization | 692.00K | 890.00K | 903.00K | 887.00K | 754.00K | 669.00K | 696.00K | 734.00K | 812.00K | 876.00K | 827.00K | 857.00K | 925.00K | 1.01M | 1.05M | 973.07K | 770.83K | 529.26K | 545.88K | 395.12K | 314.68K | 274.88K | 524.24K | 396.81K | 321.17K | 787.09K | 311.14K | 260.60K | 171.00K |
| EBITDA | -18.11M | -22.01M | -13.91M | -18.48M | -19.07M | -13.92M | -13.01M | -3.79M | -4.37M | -12.25M | -3.68M | 1.93M | 1.19M | -1.23M | 1.79M | 3.81M | 2.88M | 3.15M | 949.84K | 1.67M | 978.14K | -199.02K | 1.16M | 926.71K | 947.21K | -133.07K | 650.72K | 741.00K | -48.50K |
| EBITDA Ratio | -34.60% | -51.44% | -30.53% | -69.87% | -70.69% | -78.28% | -9.62% | -10.35% | -23.67% | -21.13% | -10.17% | 6.88% | 3.62% | 1.29% | 6.64% | 2.74% | 10.00% | 11.82% | 4.70% | 8.17% | 6.70% | -0.62% | 9.21% | 9.24% | -19.07% | -1.83% | 8.36% | 9.75% | -1.92% |
| Operating Income | -17.26M | -23.56M | -14.45M | -20.08M | -20.91M | -13.60M | -5.27M | -3.79M | -6.99M | -5.85M | -3.67M | 1.05M | -18.00K | -2.75M | 714.85K | 1.29M | 2.11M | 2.62M | 403.97K | 1.28M | 712.40K | -473.90K | 583.58K | 529.90K | -2.15M | -920.16K | 339.58K | 480.40K | -219.50K |
| Operating Income Ratio | -32.97% | -52.94% | -29.78% | -72.47% | -74.28% | -81.51% | -13.54% | -10.35% | -23.67% | -21.13% | -15.49% | 3.78% | -0.07% | -11.36% | 2.65% | 4.60% | 7.32% | 9.84% | 2.00% | 6.24% | 4.30% | -3.81% | 5.08% | 5.33% | -22.38% | -10.90% | 4.61% | 6.42% | -3.98% |
| Total Other Income/Expenses | -4.02M | 651.00K | -372.00K | 674.00K | 1.03M | -1.09M | -8.57M | -94.00K | 1.64M | -7.44M | -2.29M | -212.00K | 50.00K | 290.00K | -52.01K | 1.49M | 140.25K | 86.93K | 24.26K | -11.83K | -31.08K | -40.87K | -431.47K | 8.79K | 3.25K | -77.88K | -240.39K | -64.80K | 65.40K |
| Income Before Tax | -21.28M | -22.91M | -14.82M | -19.41M | -19.91M | -13.27M | -5.22M | -3.89M | -5.35M | -13.29M | -5.95M | 834.00K | 32.00K | -2.46M | 662.84K | 2.78M | 2.25M | 2.71M | 428.22K | 1.27M | 681.32K | -514.77K | 200.59K | 538.69K | -2.14M | -998.05K | 99.19K | 415.60K | -154.10K |
| Income Before Tax Ratio | -40.65% | -51.47% | -30.55% | -70.04% | -70.72% | -79.53% | -13.42% | -10.61% | -18.11% | -47.99% | -25.16% | 3.01% | 0.13% | -10.16% | 2.46% | 9.88% | 7.81% | 10.16% | 2.12% | 6.18% | 4.12% | -4.14% | 1.75% | 5.42% | -22.35% | -11.82% | 1.35% | 5.55% | -2.79% |
| Income Tax Expense | -2.43M | 367.00K | 380.00K | -7.50M | -260.00K | -3.78M | -156.00K | 64.00K | 25.00K | 4.00M | -1.61M | 217.00K | -77.00K | -927.00K | 67.32K | 945.42K | -148.84K | 47.57K | 32.02K | -272.72K | 31.08K | 40.87K | -211.19K | 29.27K | 35.81K | 77.88K | 240.39K | 8.30K | -65.40K |
| Net Income | -18.71M | -23.28M | -15.20M | -11.91M | -19.65M | 64.01M | -5.06M | -3.95M | -5.37M | -17.28M | -4.34M | 617.00K | 109.00K | -1.54M | 595.52K | 1.83M | 2.40M | 2.68M | 406.21K | 1.51M | 681.32K | -514.77K | 784.29K | 500.63K | -2.18M | -998.05K | 99.19K | 407.30K | -154.10K |
| Net Income Ratio | -35.75% | -52.30% | -31.33% | -42.96% | -69.79% | 383.61% | -13.02% | -10.78% | -18.19% | -62.43% | -18.34% | 2.23% | 0.43% | -6.34% | 2.21% | 6.52% | 8.34% | 10.06% | 2.01% | 7.38% | 4.12% | -4.14% | 6.83% | 5.04% | -22.75% | -11.82% | 1.35% | 5.44% | -2.79% |
| EPS | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.93 | -0.16 | -0.14 | -0.22 | -0.98 | -0.25 | 0.04 | 0.01 | -0.09 | 0.04 | 0.11 | 0.15 | 0.19 | 0.03 | 0.11 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| EPS Diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.86 | -0.16 | -0.14 | -0.19 | -0.97 | -0.25 | 0.03 | 0.01 | -0.09 | 0.03 | 0.11 | 0.13 | 0.16 | 0.03 | 0.09 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| Weighted Avg Shares Out | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 33.19M | 31.42M | 27.43M | 24.33M | 17.68M | 17.49M | 17.63M | 17.60M | 17.37M | 16.90M | 16.07M | 15.32M | 14.54M | 13.92M | 13.75M | 13.63M | 13.20M | 13.45M | 13.90M | 13.88M | 13.88M | 8.19M | 7.66M | 4.35M |
| Weighted Avg Shares Out (Dil) | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 34.37M | 31.43M | 27.45M | 27.75M | 17.76M | 17.67M | 17.79M | 17.67M | 17.37M | 17.84M | 17.09M | 17.68M | 16.91M | 15.75M | 16.80M | 13.63M | 14.41M | 14.76M | 16.07M | 13.88M | 13.88M | 8.44M | 7.66M | 4.35M |
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt...
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants...
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago.
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a...
Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third...
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third...
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Renuvion Named #1 Trusted Body Contouring Technology by Doctors*
Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla.
Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum...
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports